Evidence map›Paper›PMID 34685612›Full record

ArticleCells2021

Epigenetic DNA Modifications Upregulate SPRY2 in Human Colorectal Cancers.

Alexei J Stuckel, Shuai Zeng, Zhen Lyu, Wei Zhang, Xu Zhang, Urszula Dougherty, Reba Mustafi, Qiong Zhang, Trupti Joshi, Marc Bissonnette and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Poricoic Acid A attenuated TGF-β1-induced epithelial-mesenchymal transition in renal tubular epithelial cells through SPRY2/ERK signaling pathway.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Alexei J StuckelDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO 65212, USA.
Shuai ZengBond Life Sciences Center, University of Missouri, Columbia, MO 65201, USA.
Zhen LyuBond Life Sciences Center, University of Missouri, Columbia, MO 65201, USA.
Wei ZhangThe Robert H. Lurie Comprehensive Cancer Center, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.ORCID 0000-0003-0875-263X
Xu ZhangDepartment of Medicine, University of Illinois, Chicago, IL 60607, USA.
Urszula DoughertyDepartment of Medicine, Section of Gastroenterology, Hepatology and Nutrition, The University of Chicago, Chicago, IL 60637, USA.
Reba MustafiDepartment of Medicine, Section of Gastroenterology, Hepatology and Nutrition, The University of Chicago, Chicago, IL 60637, USA.
Qiong ZhangDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO 65212, USA.
Trupti JoshiBond Life Sciences Center, University of Missouri, Columbia, MO 65201, USA.
Marc BissonnetteDepartment of Medicine, Section of Gastroenterology, Hepatology and Nutrition, The University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0001-8420-4294
Samrat Roy ChoudhuryDepartment of Pediatrics, Arkansas Children's Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA.ORCID 0000-0002-6555-3031
Sharad KhareDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO 65212, USA.
University of Missouri · USUniversity of Chicago · USArkansas Children's Hospital · USHarry S. Truman Memorial Veterans' Hospital · USNorthwestern University · USUniversity of Illinois Chicago · USUniversity of Missouri Health System · US

Funding

NIH HHS 1R01CA240710NIH HHS 1R03CA249487Veterans Affairs 2I01BX000824
6 · The paper itself

Abstract

Conventional wisdom is that Sprouty2 (SPRY2), a suppressor of Receptor Tyrosine Kinase (RTK) signaling, functions as a tumor suppressor and is downregulated in many solid tumors. We reported, for the first time, that increased expression of SPRY2 augments cancer phenotype and Epithelial-Mesenchymal-Transition (EMT) in colorectal cancer (CRC). In this report, we assessed epigenetic DNA modifications that regulate SPRY2 expression in CRC. A total of 4 loci within

Indexed as

Epigenesis, Genetic5-MethylcytosineAdenomaBinding SitesCCCTC-Binding FactorCell Line, TumorColorectal NeoplasmsDNA MethylationGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsMembrane ProteinsPromoter Regions, GeneticRNA, MessengerTranscription, GeneticUp-Regulation5-MethylcytosineCCCTC-Binding FactorCTCF protein, humanIntracellular Signaling Peptides and ProteinsMembrane ProteinsRNA, MessengerSPRY2 protein, human5-hydroxymethylcytosinecolorectal cancerCTCF transcription factorDNA methylationepigenetic regulationSPRY2 gene expression

Identifiers

PMID34685612
PMCPMC8534322
OpenAlexW3202416447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.